Status:
RECRUITING
Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
European Union's Horizon 2020 research and innovation programme under grant agreement No 633983
Conditions:
Adult Glucocorticoid Excess
Adult Adrenal Insufficiency
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The excess of glucocorticoid, whether endogenous or exogenous, results in Cushing's syndrome, associating a particular distribution of fats (accumulation in the face and trunk), a decrease in the thic...
Detailed Description
For each participant, easily accessible biological samples will be taken (blood, urine, saliva). From these samples, a large number of molecular markers will be generated (genomics, metabolomics), in ...
Eligibility Criteria
Inclusion
- an endogenous hypercortisolism (group 1)
- a disease justifying the next start of glucocorticoid therapy (group 2)
- chronic adrenal insufficiency (group 3)
- subjects with either diabetes, hypertension or osteoporosis, but without glucocorticoid excess (control group)
- patients will have to be affiliated to a social security scheme
- patients should be able to understand the study and able to express their consent
Exclusion
- patients with reduced life expectancy, less than 2 years
- pregnant or lactating women
- patients refusing the protocol
- patients under state medical assistance
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
540 Patients enrolled
Trial Details
Trial ID
NCT04840693
Start Date
August 1 2023
End Date
December 1 2026
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Cochin
Paris, France, 75014